• Alexandre Courchesne-Loyer, Valérie St-Pierre, Marie Hennebelle, Christian-Alexandre Castellano, Mélanie Fortier, Daniel Tessier, and Stephen C Cunnane.
• Université de Sherbrooke, Department of Pharmacology and Physiology, Québec, Canada. Electronic address: alexandre.courchesne-loyer@usherbrooke.ca.
• Nutrition. 2015 Oct 1; 31 (10): 1255-9.

ObjectivesThe aim of this study was to compare the ketogenic effect of the peroxisome proliferator-activated receptor-α stimulator, bezafibrate (BEZA), alone or in combination with medium-chain triacylglycerols (MCTs) in healthy adults.MethodsEighteen healthy adults completed the study: 10 were given a therapeutic dose of BEZA (400 mg/d) for 8 wk followed by a further 4 wk of BEZA (400 mg/d) plus MCT (60 g/d). Eight other participants were given MCT alone (60 g/d) for 4 wk. All participants underwent identical metabolic study days: (a) pretreatment (the control), and after (b) BEZA combined with MCT (BEZA+MCT) or (c) an equal dose of MCT only. On the metabolic study days, a standard breakfast and lunch were given and blood samples were taken hourly to measure plasma ketones, glucose, and fatty acids.ResultsThe combination of BEZA+MCT increased ketones twofold during the metabolic study day. The addition of BEZA increased early ketogenic efficiency of MCT by 2.5-fold but did not result in higher peak or mean concentration of ketones during the metabolic study day. No other differences were seen in plasma metabolites or insulin during metabolic study days. On the final metabolic study day, MCT or BEZA+MCT had different effects on the plasma acetoacetate-to-β-hydroxybutyrate ratio compared with control.ConclusionsBEZA mildly potentiated the ketogenic action of MCT but did not increase peak plasma ketone concentration or overall ketone production during the metabolic study day.Copyright © 2015 Elsevier Inc. All rights reserved.

29 keywords...

hide…